Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial

• Published in: Journal of clinical lipidology Vol. 10; no. 1; pp. 181 - 191.e2
• Main Authors: Bays, Harold E., Hallén, Jonas, Vige, Runar, Fraser, David, Zhou, Rong, Hustvedt, Svein Olaf, Orloff, David G., Kastelein, John J.P.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2016
• Subjects: Adolescent; Adult; Aged; Apolipoprotein C-III; Cardiovascular; Double-Blind Method; Fatty Acids, Omega-3 - chemistry; Fatty Acids, Omega-3 - pharmacology; Fatty Acids, Omega-3 - therapeutic use; Female; Humans; Hypertriglyceridemia; Hypertriglyceridemia - blood; Hypertriglyceridemia - drug therapy; Hypolipidemic Agents - chemistry; Hypolipidemic Agents - pharmacology; Hypolipidemic Agents - therapeutic use; Icosabutate; Male; Middle Aged; Placebos; Remnants; Triglycerides; Triglycerides - blood; Young Adult; Remnants; Triglycerides; Icosabutate; Apolipoprotein C-III; Hypertriglyceridemia
• ISSN: 1933-2874; 1876-4789
• DOI: 10.1016/j.jacl.2015.10.012

Icosabutate is a structurally enhanced omega-3 fatty acid molecule developed with the aim of achieving improved triglyceride (TG)-lowering efficacy, increased potency, and preserved safety compared with conventional prescription omega-3 fatty acid. To evaluate the efficacy and safety of icosabutate 600 mg once daily in patients with very high TGs. After a 6-8 week run-in period, men and women with TG levels ≥500 mg/dL and ≤1500 mg/dL were randomized to double-blind treatment with placebo or icosabutate 600 mg for 12 weeks. The primary end point was % change from baseline in TGs at 12 weeks. A total of 87 subjects were randomized. At baseline, median TG (interquartile range) levels were 611 (543–878) and 688 (596–892) mg/dL, and the median change after 12 weeks of treatment was −51% and −17%, respectively, for a placebo-corrected change of −33% (P < .001). Adjusted for placebo, icosabutate significantly reduced very low–density lipoprotein cholesterol (−36%, P < .001), remnant lipoprotein cholesterol (−34%, P < .001), apolipoprotein (Apo) C-III (−35%, P < .001), trended toward reduced non–high-density lipoprotein cholesterol (−7%, P = .064); significantly increased high-density lipoprotein cholesterol (18%, P < .001) and low-density lipoprotein cholesterol (28%, P < .001), with a trend of an increased lipoprotein (a; 10%, P = .054). No changes were observed in total cholesterol, apolipoprotein B, or apolipoprotein A1. Fasting plasma glucose was unchanged, whereas fasting plasma insulin was reduced (P = .001) with icosabutate. Icosabutate was generally well tolerated. Treatment with icosabutate once daily significantly reduced TG, very low–density lipoprotein cholesterol, and Apo C-III levels in patients with very high TG levels. This trial was registered at www.clinicaltrials.gov as NCT01893515. •Icosabutate is a first-in-class structurally enhanced fatty acid.•Icosabutate was tested in hypertriglyceridemic subjects.•Triglycerides were significantly reduced vs placebo.•Icosabutate appeared safe and well tolerated.